NBP - NASDAQ

NovaBridge Biosciences

NBP·NASDAQ

$1.75

-0.57%

HealthcareBiotechnology

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$201.72M

EPS-0.1600

P/E Ratio-10.94

Earnings Date06/30/2026

37.24M

Assets

-98%

3Y-99.0%

5Y-99.0%

10Y-96.0%

4.23M

Total Liabilities

-95%

3Y-100.0%

5Y-99.0%

10Y-100.0%

33.02M

Total Equity

-98%

3Y-99.0%

5Y-99.0%

10Y+458.0%

NovaBridge Biosciences Funding & Solvency Profile

NBP · NASDAQ

Current Assets

Cash & Cash Equivalents30.11M

Net Receivables256.33K

Inventory0.00

Other Current Assets0.00

Total Current Assets31 M

Non-Current Assets

Property, Plant & Equipment421.59K

Goodwill & Intangible Assets0.00

Long-Term Investments5.32M

Other Non-Current Assets402.00K

Total Non-Current Assets6 M

Total Assets

37.24M

Financial Health Analysis

Current Ratio

8.09x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.13x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

27 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

83% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

NovaBridge Biosciences Balance Sheet

NBP • NASDAQ

NovaBridge Biosciences Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	30.1M	498.2M	291.5M	3.2B	552.8M	4.8B	1.1B	1.6B	307.9M
Short-Term Investments	30K	767.4M	20.2M	235.4M	118.2M	31.5M	32M	256M	266.2M
Cash & Short-Term Investments	30.1M	1.3B	311.7M	3.4B	671M	733.2M	1.2B	1.8B	574.2M
Net Receivables	256.3K	8.6M	1.8M	4.8M	61M	71.3M	8M	9.4M	628.2K
Accounts Receivables	0.0	7.6M	0.0	1.2M	5.2M	54.7M	0.0	7.5M	0.0
Other Receivables	255.6K	948.8K	1.8M	3.6M	55.8M	16.5M	6.1M	1.9M	49.6K
Inventory	0.0	0.0	0.0	-80.3M	4.3M	0.0	-55.9M	-215.6M	0.0
Prepaids	698.4K	15.5M	670K	9.6M	14M	13.4M	880K	3.2M	2.6M
Other Current Assets	0.0	0.0	15.7M	243M	0.0	4.5B	238.9M	218.9M	114.9M
Total Current Assets	31.1M	1.3B	329.9M	3.6B	750.2M	5.3B	1.4B	2B	691.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	421.6K	27.7M	5.6M	124M	24.9M	40.3M	46.5M	27.7M	22.3M
Goodwill	0.0	0.0	0.0	162.6M	25.5M	162.6M	162.6M	162.6M	162.6M
Intangible Assets	0.0	0.0	0.0	118.9M	18.8M	120.4M	148.8M	148.8M	148.8M
Goodwill & Intangible Assets	0.0	0.0	0.0	281.5M	44.3M	283M	311.4M	311.4M	311.4M
Long-Term Investments	5.3M	225M	0.0	30.9M	55.2M	664.8M	0.0	0.0	0.0
Other Non-Current Assets	402K	10M	33.5M	10.9M	4.2M	2M	18.3M	0.0	0.0
Total Non-Current Assets	6.1M	262.7M	39M	447.2M	128.6M	990.1M	376.3M	339.1M	333.8M
Total Assets	37.2M	1.6B	368.9M	4.1B	878.7M	6.3B	1.7B	2.4B	1B
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	0.0	0.0	16.7M	8.2M	34.1M	6.6M	2.7M	844K
Other Payables	0.0	0.0	0.0	16.7M	8.2M	34.1M	6.6M	11M	844K
Accrued Expenses	2.4M	55M	7.8M	84.8M	84.5M	51.3M	239.8M	67.7M	12.2M
Short Term Debt	0.0	0.0	0.0	2.7M	0.0	-34.8M	50M	80M	99M
Capital Lease Obligations (Current)	127.4K	6M	626K	3.5M	4.8M	8.1M	6.8M	0.0	-16.6M
Deferred Revenue	0.0	773.7K	0.0	2.2M	371.7K	9.9M	3.9M	14.2M	15.8M
Other Current Liabilities	1.3M	0.0	49.7M	549.9M	0.0	507.5M	281.3M	195.7M	67.3M
Total Current Liabilities	3.8M	61.7M	58.1M	659.7M	97.9M	576.1M	588.5M	346.2M	195.1M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	5.5M	68.2M	67M	114M
Deferred Revenue (Non-Current)	0.0	0.0	106K	0.0	37.5M	9M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	-9M	0.0	0.0	0.0
Other Non-Current Liabilities	73.1K	3.8K	64.8M	373.5M	15.2M	119.4M	3.1B	2.9B	1B
Total Non-Current Liabilities	384.1K	22.4M	68.2M	405.6M	65.5M	130.5M	3.2B	3B	1.1B
Capital Lease Obligations	438.5K	28.3M	3.9M	35.5M	17.6M	13.6M	14.3M	0.0	0.0
Total Liabilities	4.2M	84.1M	126.3M	1.1B	163.4M	706.6M	3.8B	3.3B	1.3B
SHAREHOLDERS' EQUITY
Treasury Stock	-720.8K	-45.4M	-8M	-21.2M	0.0	0.0	0.0	-1K	-1K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	3.1B	2.9B	710.3M
Common Stock	3.9K	138.7K	19K	132K	19.8K	114K	6K	6K	6K
Additional Paid-In Capital	218.3M	10.7B	1.5B	9.6B	1.4B	7.7B	55.7M	0.0	8M
Retained Earnings	-190.5M	-9.4B	-1.3B	-6.8B	-683.2M	-2B	-2.5B	-1B	-357.9M
Accumulated Other Comprehensive Income/Loss	5.9M	243.7M	39.8M	216.7M	-29.3M	-50.8M	70.1M	59.4M	5.7M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3B	759.5M
Total Stockholders' Equity	33M	1.5B	242.6M	3B	715.3M	5.6B	-2B	-955.1M	-299.8M
Total Equity	33M	1.5B	242.6M	3B	715.3M	5.6B	-2B	-955.1M	5.9M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	305.7M
SUMMARY
Total Liabilities & Equity	37.2M	1.6B	368.9M	4.1B	878.7M	6.3B	1.7B	2.4B	1B
Total Investments	5.4M	992.3M	20.2M	266.3M	173.4M	696.4M	32M	256M	266.2M
Total Debt	438.5K	28.3M	3.9M	38.3M	17.6M	13.6M	132.5M	147M	213M
Net Debt	-29.7M	-469.9M	-287.6M	-3.2B	-535.2M	-4.7B	-1B	-1.4B	-94.9M
Shares Outstanding	50,115,675	50,115,675	50,115,675	50,115,675	50,115,675	50,115,675	50,115,675	50,115,675	50,115,675

SEC Filings

NBP - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
6-K 6-K 2026 Q2 Q2	April 22, 2026	April 22, 2026	2026	View Filing
6-K 6-K 2026 Q2 Q2	April 07, 2026	April 07, 2026	2026	View Filing
20-F 20-F 2025 FY FY	April 07, 2026	December 31, 2025	2025	View Filing
6-K 6-K 2026 Q1 Q1	March 16, 2026	March 16, 2026	2026	View Filing
6-K 6-K 2026 Q1 Q1	March 09, 2026	March 09, 2026	2026	View Filing
6-K 6-K 2026 Q1 Q1	March 03, 2026	March 03, 2026	2026	View Filing
6-K 6-K 2026 Q1 Q1	February 25, 2026	February 25, 2026	2026	View Filing
6-K 6-K 2026 Q1 Q1	February 19, 2026	February 19, 2026	2026	View Filing
6-K 6-K 2026 Q1 Q1	February 17, 2026	February 17, 2026	2026	View Filing
6-K 6-K 2026 Q1 Q1	February 06, 2026	February 06, 2026	2026	View Filing

Showing 1 to 10 of 161 filings

Related Guides

Blog Categories

Continue your NBP research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.